DE69317494D1 - Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten - Google Patents

Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten

Info

Publication number
DE69317494D1
DE69317494D1 DE69317494T DE69317494T DE69317494D1 DE 69317494 D1 DE69317494 D1 DE 69317494D1 DE 69317494 T DE69317494 T DE 69317494T DE 69317494 T DE69317494 T DE 69317494T DE 69317494 D1 DE69317494 D1 DE 69317494D1
Authority
DE
Germany
Prior art keywords
treatment
amino acids
compositions containing
diabetes mellitus
containing mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69317494T
Other languages
English (en)
Other versions
DE69317494T2 (de
Inventor
Yves Sauvaire
Gerard Ribes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
JOUVENET SOC CIV
Original Assignee
JOUVENET SOC CIV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JOUVENET SOC CIV filed Critical JOUVENET SOC CIV
Publication of DE69317494D1 publication Critical patent/DE69317494D1/de
Application granted granted Critical
Publication of DE69317494T2 publication Critical patent/DE69317494T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69317494T 1992-09-07 1993-09-01 Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten Expired - Fee Related DE69317494T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9210644A FR2695317B1 (fr) 1992-09-07 1992-09-07 Composition apte à stimuler la sécrétion d'insuline destinée au traitement du diabète non insulino-dépendant.

Publications (2)

Publication Number Publication Date
DE69317494D1 true DE69317494D1 (de) 1998-04-23
DE69317494T2 DE69317494T2 (de) 1998-11-05

Family

ID=9433260

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69317494T Expired - Fee Related DE69317494T2 (de) 1992-09-07 1993-09-01 Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten

Country Status (9)

Country Link
US (1) US5470879A (de)
EP (1) EP0587476B1 (de)
JP (1) JP2655044B2 (de)
AT (1) ATE164064T1 (de)
CA (1) CA2105502C (de)
DE (1) DE69317494T2 (de)
DK (1) DK0587476T3 (de)
ES (1) ES2116421T3 (de)
FR (1) FR2695317B1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2745718B1 (fr) * 1996-03-08 1998-05-07 Gestion Jouvenet Soc Civ De Composition antidiabetique a base de 4-hydroxyisoleucine
US6042834A (en) * 1997-01-29 2000-03-28 Baraka; Mohamed Wasif Herbal composition for diabetes and method of treatment
CA2284192A1 (en) * 1997-03-24 1998-10-01 Galderma Research & Development, S.N.C. Retinoid related molecules for the treatment of non-insulin dependent diabetes mellitus
FR2797767B1 (fr) * 1999-08-27 2002-06-14 Centre Nat Rech Scient Utilisation d'acides amines pour la fabrication de medicaments destines au traitement des insulino-resistances
CN100475757C (zh) * 2000-02-01 2009-04-08 斯特维亚私人有限公司 用于饮食补充或用于制备治疗非胰岛素依赖性糖尿病、高血压和/或代谢综合征的药物的物质
US6329167B1 (en) * 2000-12-05 2001-12-11 Bruce K. Patterson Method of testing adequacy of cells in a specimen
EP1358230B1 (de) * 2000-12-20 2006-06-07 ExxonMobil Chemical Patents Inc. Verfahren zur polymerisation von kationisch polymerisierbaren monomeren
US6551627B1 (en) * 2001-05-03 2003-04-22 Holomed Pharmaceuticals, Ltd. Medicinal herbal compounds for the prevention and treatment of diabetes
AU2003234146A1 (en) * 2002-04-22 2003-11-03 Experimental And Applied Sciences, Inc. Food supplements containing 4-hydroxyisoleucine and creatine
US7338675B2 (en) * 2002-05-10 2008-03-04 Tsi Health Sciences, Inc. Fenugreek seed bio-active compositions and methods for extracting same
US20050176827A1 (en) * 2002-05-10 2005-08-11 Lee Steve S. Compositions and methods for glycogen synthesis
US20060159746A1 (en) * 2003-03-18 2006-07-20 Troup John P Compositions comprising fatty acids and amino acids
FR2852841B1 (fr) * 2003-03-28 2006-08-04 Vincience Composition cosmetique ou pharmaceutique comprenant des acides amines, utilisations et procedes de traitement
US7674486B2 (en) * 2003-05-14 2010-03-09 Indus Biotech Pvt. Ltd. Synergistic composition for the treatment of diabetes mellitus
JP4353982B2 (ja) * 2003-05-14 2009-10-28 インダス バイオテック ピーブイティ． エルティーディー． 糖尿病処置用相乗作用組成物
US7736676B2 (en) * 2003-05-14 2010-06-15 Indus Biotech Pvt. Ltd. Synergistic composition for the treatment of diabetes mellitus
FR2856297B1 (fr) * 2003-06-18 2005-08-05 Caster Utilisation de (2s,3r,4s)-4-hydroxyisoleucine dans des compositions cosmetiques pour application topique
CN1313435C (zh) * 2003-10-27 2007-05-02 成都华高药业有限公司 一种从葫芦巴中提取4－羟基异亮氨酸制品的新方法
MXPA06004698A (es) * 2003-10-27 2006-07-05 Innodia Inc Metodos y composiciones para utilizarse en el tratamiento de la diabetes.
US20080182801A1 (en) * 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20050226948A1 (en) * 2004-03-02 2005-10-13 Lee Steve S Methods for enhancing the transport of glucose into muscle
US20050233014A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for affecting homeostasis and metabolism in a mammalian body
US7645466B2 (en) 2004-03-02 2010-01-12 Tsi Group Limited Methods for deriving, isolating, and/or extracting amino acid compositions from Fenugreek seed
US20050233013A1 (en) * 2004-03-02 2005-10-20 Lee Steve S Methods for enhancing the transport of glucose for balancing blood sugar levels
US20090076111A1 (en) * 2004-03-02 2009-03-19 Lee Steve S Methods for improving glycemic control in humans
JP2008530197A (ja) * 2005-02-18 2008-08-07 イノディア インク． ４−ヒドロキシイソロイシンの類似体及びその使用
CN101252926A (zh) * 2005-03-22 2008-08-27 因诺迪亚有限公司 用于预防和治疗肥胖症及相关综合征的化合物与组合物
GB0512726D0 (en) * 2005-06-22 2005-07-27 Btg Int Ltd Multiple sclerosis therapy and diagnosis
FR2887773B1 (fr) * 2005-07-01 2008-05-30 Soc Extraction Principes Actif Utilisation d'un acide amine en tant qu'agent actif inducteur de la synthese des proteines sirt dans les cellules de la peau.
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
WO2007107008A1 (en) * 2006-03-22 2007-09-27 Innodia Inc. Compounds and compositions for use in the prevention and treatment of disorders of fat metabolism and obesity
CA2678990A1 (en) 2007-02-22 2008-08-28 Ajinomoto Co., Inc. Method for purifying 4-hydroxyisoleucine
RU2395580C2 (ru) 2007-12-21 2010-07-27 Закрытое акционерное общество "Научно-исследовательский институт Аджиномото-Генетика" (ЗАО АГРИ) Способ конструирования бактерии-продуцента (2s,3r,4s)-4-гидрокси-l-изолейцина, бактерия-продуцент (2s,3r,4s)-4-гидрокси-l-изолейцина и способ продукции (2s,3r,4s)-гидрокси-l-изолейцина или его соли
US8496977B2 (en) 2009-08-12 2013-07-30 Munisekhar Medasani Natural extract from whole banana fruit (Musa Spp)
WO2011021717A2 (en) 2009-08-21 2011-02-24 Ajinomoto Co.,Inc. Method for producing hydroxylated amino acids

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2315916A2 (fr) * 1976-03-23 1977-01-28 Univ Johns Hopkins Melanges therapeutiques comprenant des analogues alpha hydroxy acides d'acides amines essentiels et leur administration a l'homme en vue de l'amelioration de la synthese proteique et la suppression de la formation d'uree
US5132113A (en) * 1990-10-26 1992-07-21 Maurizio Luca Nutritional composition containing essential amino acids

Also Published As

Publication number Publication date
FR2695317A1 (fr) 1994-03-11
JP2655044B2 (ja) 1997-09-17
EP0587476B1 (de) 1998-03-18
ATE164064T1 (de) 1998-04-15
DK0587476T3 (da) 1998-12-07
US5470879A (en) 1995-11-28
CA2105502C (fr) 2000-11-21
EP0587476A1 (de) 1994-03-16
DE69317494T2 (de) 1998-11-05
JPH06157302A (ja) 1994-06-03
FR2695317B1 (fr) 1995-03-10
ES2116421T3 (es) 1998-07-16
CA2105502A1 (fr) 1994-03-08

Similar Documents

Publication Publication Date Title
DE69317494D1 (de) Zusammensetzungen, die mono oder polyhydroxylierte Aminosäuren zur Behandlung des Insulinunabhängigen Diabetes Mellitus enthalten
ATE31625T1 (de) Pharmazeutisches mittel zur behandlung des diabetes mellitus.
IL96549A0 (en) Production of a biologically active protein
ATE96678T1 (de) Verfahren zur verminderung von hautirritationen bei anwendung von durchdringungsverstaerkenden arzneimittelzusammensetzungen.
AU2118488A (en) Improvements in or relating to methods of treating damaged skin
ATE73657T1 (de) Verwendung von gamma-linolensaeure und verwandten verbindungen zur herstellung eubnes arzneimittels zur behandlung von endometriose.
FI971951A0 (fi) 2,2-dikloroalkaanikarboksyylihapot, menetelmät niiden valmistamiseksi, niitä sisältävät lääkkeet, ja niiden käyttö insuliiniresistanssin hoitoon
AU4438489A (en) Pharmaceutical compositions containing n-(3,4- dimethoxycinnamoyl)anthranilic acid
NO902800L (no) Fremgangsmaate for fremstilling av 11beta-aryl-4-oestrener.
PH25313A (en) Carboxylic acid derivatives, pharmaceutical compositions containing them
ATE268587T1 (de) Gebrauch von silicongummi zur stabilisierung von ascorbinsaüre und vorbereitungen die diese zusammensetzungen enthalten
MX24839A (es) 3-arilcarbonil-1-aminoalquilo-1h-indoles, proceso para su preparacion y composicion farmaceutica quelos contiene.
HUT55034A (en) Process for producing peptides with hemoregulating effect and pharmaceutical compositions comprising such compounds as active ingredient
MD1360B2 (en) A fungicidal composition, process for control and prevention of plants Oomycetes infection
DE69104083D1 (de) Neue Antiulcus-Substanz.
DE69825981D1 (de) 4,5-dihydroxy-2-cyclopenten-1-on für die Behandlung von Diabetes Mellitus
MX170055B (es) , "composicion insecticida y procedimiento para su obtencion
DE69402004D1 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
ATE194076T1 (de) Verwendung von n,s-diacetylcystein-ethylester (dacee) zur herstellung eines medikaments zur behandlung viraler erkrankungen
DE69930624D1 (de) Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
DE60318423D1 (de) Behandlung des typ 1 diabetes vor und nach expression von prädispositionsmarkern
NO913685L (no) Fremgangsmaate for fremstilling av kalsiumopptaksinhibitorer.
ATE66815T1 (de) Arzneimittel enthaltend einen aus den peyer'schen plaques hergestellten organextrakt zur behandlung bei diabetes mellitus und pankreatitis.
DE69225306T2 (de) 1-Oleoylazacycloheptanon(2) enthaltende Arzneimittel zur Verstärkung des Transports durch biologische Membranen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee